Skip to main content

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.* The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening and fetal RhD screening in one integrated report. The screen has greater than 98% analytical sensitivity and greater than 99% analytical specificity.1 With results expected to be delivered in approximately 10 days, the FirstGene screen is designed to help...

Continue reading

Ignitis Group makes final investment decision on 107.2 MW Tume BESS in Latvia

AB “Ignitis grupė” (hereinafter – the Group) informs that on 21 July, the Group’s subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) made a final investment decision on a 107.2 MW power and 214.5 MWh storage capacity battery energy storage system (hereinafter – Tume BESS) in Latvia. Tume BESS will be integrated with 173.6 MW Tume solar farm, which is currently under construction by Ignitis Renewables and located in Tukums municipality in Latvia. Tume BESS will use the same connection and infrastructure to the power grid. The construction works on Tume BESS are expected to start in 2026, and the COD is estimated for 2028. The total investment amount is approximately EUR 35 million. The Group is currently developing a 291 MW BESS project portfolio in Lithuania (link) to support the integration of renewables by helping...

Continue reading

Ignitis Group makes final investment decision on 107.2 MW Tume BESS in Latvia

AB “Ignitis grupė” (hereinafter – the Group) informs that on 21 July, the Group’s subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) made a final investment decision on a 107.2 MW power and 214.5 MWh storage capacity battery energy storage system (hereinafter – Tume BESS) in Latvia. Tume BESS will be integrated with 173.6 MW Tume solar farm, which is currently under construction by Ignitis Renewables and located in Tukums municipality in Latvia. Tume BESS will use the same connection and infrastructure to the power grid. The construction works on Tume BESS are expected to start in 2026, and the COD is estimated for 2028. The total investment amount is approximately EUR 35 million. The Group is currently developing a 291 MW BESS project portfolio in Lithuania (link) to support the integration of renewables by helping...

Continue reading

Ferrellgas Announces Extension of CEO Tamria Zertuche’s Employment Agreement

Leadership Continuity Reinforces Company’s Commitment to Growth and Innovation LIBERTY, Mo., July 21, 2026 (GLOBE NEWSWIRE) — Ferrellgas, the nation’s second largest propane distributor, today announced that President and Chief Executive Officer Tamria Zertuche has agreed to extend her executive employment agreement with the Company, ensuring continued executive leadership as Ferrellgas executes on its long-term strategic vision. “Tamria has been an exceptional leader for Ferrellgas, and her continued partnership is a reflection of the confidence our organization has in the direction we are headed,” said Jim Ferrell, Chairman of the Board. “Her proven ability to lead with integrity, drive operational excellence, and inspire our team makes her the right person to lead Ferrellgas into its next chapter.” Since assuming the role of...

Continue reading

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026. Details of the event are as follows: Presenter: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical OfficerDate/Time: Wednesday, July 22, 12:30 PM ETLocation: VirtualRegister to Attend: H.C. Wainwright Registration About OKYO PharmaOKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment...

Continue reading

Paylocity Launches Ignite AI—Redefining Industry AI Leadership

New agents automate work across the platform, while the centralized Paylocity Ignite AI Hub provides control, measures impact, and manages adoption SCHAUMBURG, Ill., July 21, 2026 (GLOBE NEWSWIRE) — Paylocity, a leading provider of HCM, Finance, and IT solutions, today introduced Paylocity Ignite AI, its platform-wide AI with agents that automate manual work, help reduce risk, and enable teams to move faster. Embedded throughout Paylocity’s platform, Ignite AI brings data, insights, and automation into moments where decisions are made and work gets done. Purpose-Built Agents That Help Teams Take Action Ignite AI includes new, purpose-built agents that automate tasks across pay, time, recruiting, and other areas where work often slows down. Answer & Insight Agent Getting answers from your data today means running reports, exporting...

Continue reading

PensionBee and ASC Partner to Modernize Automatic Rollovers for Third-Party Administrators

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) — PensionBee, a leading online retirement provider, and Actuarial Systems Corporation (ASC), a premier provider of retirement plan automation software, today announced a partnership to simplify automatic rollovers for ASC clients and other third-party administrators (TPAs) and their clients. The new integration will reduce complexity, streamline compliance, and save valuable time for retirement plan administrators, expanding access to PensionBee’s participant-friendly Automatic Rollover IRA solution. “We’re thrilled to partner with ASC to simplify force-outs and plan terminations for our clients,” said Helene Obrien, VP of Employer Partnerships at PensionBee. “Force-outs increasingly carry significant reputational and fiduciary weight, and this integration makes it even easier for administrators...

Continue reading

LPL Welcomes John and Brian Bizjack to Ascendus Financial Advisors

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors John Bizjack and Brian Bizjack have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform, aligned with Ascendus Financial Advisors, an existing firm supporting LPL-affiliated advisors. They reported serving approximately $145 million in advisory, brokerage and retirement plan assets* and join LPL from Morgan Stanley. Based in Tulsa, Okla., they operate a family-owned practice, with brothers John and Brian continuing in the path of their father Paul, who served as a financial advisor for 40 years. Their client base consists of families and individuals nearing or in retirement, as well as young clients looking to start saving and investing. The Bizjacks have known and served many of their clients across...

Continue reading

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trialLower rate of minimal residual disease (MRD) Higher ctDNA clearance with IMNN-001 vs. control Highly favorable safety and tolerability profileStudy, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001’s unique mechanism of remodeling the tumor immune microenvironment LAWRENCEVILLE, N.J., July 21, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced new positive preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of IMNN-001, conducted in combination with standard of care neoadjuvant...

Continue reading

Arteris Deployed by Speedata for Data Center Compute

Arteris network-on-chip (NoC) IP supports scalable high-performance data movement in Speedata’s purpose-built Analytics Processing Unit (APU) for large-scale data analytics workloads CAMPBELL, Calif., July 21, 2026 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced that Speedata, developer of the purpose-built Analytics Processing Unit (APU), has deployed Arteris FlexNoC technology in its Callisto processor. The Speedata APU runs Apache Spark SQL, AI Data Preparation, Agentic Analytics, and batch ETL workloads natively in silicon, delivering faster performance and lower total cost of ownership. Organizations increasingly rely on large-scale analytics to extract insights from growing volumes of structured and unstructured data....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.